Institutions Own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares but Retail Investors Control 46% of the Company
ProQR Announces Presentation on Its Axiomer RNA Editing Technology at RNA Editing Summit
Shareholders in ProQR Therapeutics (NASDAQ:PRQR) Are in the Red If They Invested Five Years Ago
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital
HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target